20 research outputs found
Sustainability & Environmental Footprint
No full textSustainability is the ability to survive successfully. It pertains to the environmental, social and economical realms. Environmental footprint is the performance measurement of an activity or a product. Environmental impact categories may be either consumptions from or emissions to air, water and soil. The life cycle phases of a product are the series of stages from raw materials acquisition to final disposal. Life Cycle Assessment - per ISO 14040 - starts by defining the goal and scope. It ends by an adequate interpretation of the impact assessment. A case study is reviewed: the life cycle assessment framework of carrier supermarket bags in the United Kingdom, in 2006
A Review of Fatherhood Related Issues in the Country of Lebanon
No full textFatherhood issues in the country of Lebanon remain largely unexplored and undocumented. This review serves as a basis for fatherhood issues and presents a snapshot of the current situation with a background of some of the most related challenges affecting the issue of parenting in Lebanon. In addition, this review lays the background of how these challenges affect women of childbearing age who often end up raising their families on their own. Cultural and religious beliefs as well as factors relating to political influences in the Middle East region are discussed. The author concludes with a set of lessons learned
Another Cancerous Sinus Syndrome: Not All in the Head
No full textTransient episodes of strong taste associated with odor.A 21-year old female with an 8-month history of transient, unusual odor and taste. Previous history significant for amblyopia treated with glasses at age 5.VA: 20/20 OU declining to 20/70 OU; RAPD OSN/AAtypical hyaline cartilage with well-differentiated chondroid tissueSurgery1. Ahmed SK, Lee WC, Irving RM, Walsh AR. Is Ollier\u27s disease an understaging of Maffucci\u27s syndrome? Journal of Laryngology & Otology. 113(9):861-4, Sep 1999. 2. Balcer LJ, Galetta SL, Cornblath WT, Liu GT. Neuro-ophthalmologic manifestations of Maffucci\u27s syndrome and Ollier\u27s disease. Journal of Neuro-Ophthalmology. 19(1):62-6, 1999. 3. Bovee JV, van Roggen JF, Cleton-Jansen AM, Taminiau AH, van der Woude HJ, Hogendoorn PC. Malignant progression in multiple endochondromatosis (Ollier\u27s disease): an autopsy-based molecular genetic study. Human Pathology. 31(10):1299-303, 2000. 4. Brazier DJ, Roberts-Harry J, Crockard A. Intracavernous chondrosarcoma associated with Ollier\u27s disease. British Journal of Ophthalmology. 77(9):599-600, 1993. 5. Clifton AG, Kendall BE, Crockard HA, Hughes T. Intracranial chondrosarcoma in a patient with Ollier\u27s disease. British Journal of Radiology. 64(763):633-6, 1991. 6. Ghogawala Z, Moore M, Strand R, Kupsky WJ, Scott RM. Clival chondroma in a child with Ollier\u27s disease. Case report. Pediatric Neurosurgery. 17(1):53-6, 1991-92. 7. Hasbini A, Lartigau E, Le Pechoux C, Acharki A, Vanel D, Genin J, Le Cesne A. Chondrosarcoma in Ollier\u27s disease. Apropos of 2 cases and review of the literature. Cancer Radiotherapie. 2(4):387-91, 1998. 8. Hofman S, Heeg M, Klein JP, Krikke AP. Simultaneous occurrence of a supra- and an infratentorial glioma in a patient with Ollier\u27s disease: more evidence for non-mesodermal tumor predisposition in multiple enchondromatosis. Skeletal Radiology. 27(12):688-91, 1998. 9. Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG, Bell RS, Juppner H, Andrulis IL, Wunder JS, Alman BA. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nature Genetics. 30(3):306-10, 2002. 10. Jesus-Garcia R, Bo Giovanni JC, Korukian M, Boatto H, Seixas MT, Laredo J. Use of the Ilizarov external fixator in the treatment of patients with Ollier\u27s disease. Clinical Orthopaedics & Related Research. (382):82-6, 2001. 11. McDermott AL, Dutt SN, Chavda SV, Morgan DW. Maffucci\u27s syndrome: clinical and radiological features of a rare condition. Journal of Laryngology & Otology. 115(10): 845-7, 2001. 12. Nakase H, Nagata K, Yonezawa T, Morimoto T, Sakaki T. Extensive parasellar chondroma with Ollier\u27s disease. Acta Neurochirurgica. 140(1):100-1, 1998. 13. Pospiech J, Mehdorn HM, Reinhardt V, Grote W. Sellar chondroma in a case of Ollier\u27s disease. Neurochirurgia. 32(1):30-5, Jan 1989. Ramina R, Coelho Neto M, Meneses MS, Pedrozo AA. Maffucci\u27s syndrome associated with a cranial base chondrosarcoma: case report and literature review. Neurosurgery. 41(1):269-72, 1997. 14. Rawlings CE 3rd, Bullard DE, Burger PC, Friedman AH. A case of Ollier\u27s disease associated with two intracranial gliomas. Neurosurgery. 21(3): 400-3,1987. 15. Schmidinger A, Rosahl SK, Vorkapic P, Samii M. Natural history of chondroid skull base lesions - case report and review. Neuroradiology, 44(3):268-71, March 2002. 16. Tibbs RE Jr, Bowles AP Jr. Maffucci\u27s syndrome associated with a cranial base chondrosarcoma: case report and literature review. Neurosurgery. 43(2):397, 1998. 17. Traflet RF, Babaria AR, Barolat G, Doan HT, Gonzalez C, Mishkin MM. Intracranial chondroma in a patient with Ollier\u27s disease. Case report. Journal of Neurosurgery. 70(2):274-6, 1989
Radiothérapie hyperfractionnée accélérée alternée avec une chimiothérapie dans le cancer du sein inflammatoire non métastatique
No full textA randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer
No full textIndications et perspectives de l’hormonoradiothérapie des cancers de prostate à haut risque
No full textInternational audienc
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
No full textInternational audienceBackgroundDarolutamide and enzalutamide are second-generation androgen receptor inhibitors with activity in men with castrate-resistant prostate cancer (CRPC) and different toxicity profiles.ObjectiveODENZA is a prospective, randomized, multicenter, cross-over, phase 2 trial designed to assess preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic CRPC (mCRPC).Design, setting, and participantsPatients were randomized 1:1 to receive either darolutamide 1200 mg/d for 12 wk followed by enzalutamide 160 mg/d for 12 wk or enzalutamide followed by darolutamide. In both arms, the second treatment was given in absence of cancer progression.Outcome measurements and statistical analysisThe primary endpoint was patient preference between the two drugs, as assessed by a preference questionnaire (p value calculated with the Prescott test). After week 24, patients entered an extension period during which they received their preferred treatment until progression or toxicity. The main secondary objectives included reasons for patient preference, response at week 12, tolerance of each drug, and measurement compared with baseline of cognitive outcomes assessed using tablet questionnaires.Results and limitationsOverall, 249 patients, with a median age of 72 yr, were randomized. Among the 200 patients who fulfilled the preplanned criteria for the evaluation of the primary endpoint of preference, 97 (49% [41; 56]), 80 (40% [33; 47]), and 23 (12% [7; 16]) chose darolutamide, chose enzalutamide, and had no preference, respectively (p = 0.92). Reduced fatigue, easier administration, and better quality of life were the main criteria that influenced patient choice. A moderate benefit in episodic memory from darolutamide was observed for the acquisition of new information (least square [LS] means difference = 2.2, effect size = 0.5) and for the recall of that information after a brief delay (LS means difference = 0.7, effect size = 0.3). Using the Brief Fatigue Inventory questionnaire, patients reported greater fatigue with enzalutamide (3.3 [3.0; 3.6]) than with darolutamide (2.7 [2.4; 3.0]). There was no difference in terms of depression, seizures, and falls.ConclusionsThe study did not show a difference in preference between the two treatments. In men with mCRPC, darolutamide was associated with a clinically meaningful benefit in episodic memory and less fatigue compared with enzalutamide.Patient summaryPreference between darolutamide and enzalutamide was well balanced in men with castrate-resistant prostate cancer. Darolutamide was associated with a significant benefit in verbal learning and less fatigue compared with enzalutamide
Radiotherapy of T4M0 prostate cancer : A multicentric retrospective analysis
No full textInternational audienc
Maternal SARS-COV-2 infection and prematurity: the Southern Michigan COVID-19 collaborative
No full textOBJECTIVE: COVID-19 has been reported to increase the risk of prematurity, however, due to the frequent absence of unaffected controls as well as inadequate accounting for confounders in many studies, the question requires further investigation. We sought to determine the impact of COVID-19 disease on preterm birth (PTB) overall, as well as related subcategories such as early prematurity, spontaneous, medically indicated preterm birth, and preterm labor (PTL). We assessed the impact of confounders such as COVID-19 risk factors, a-priori risk factors for PTB, symptomatology, and disease severity on rates of prematurity.
METHODS: This was a retrospective cohort study of pregnant women from March 2020 till October 1st, 2020. The study included patients from 14 obstetric centers in Michigan, USA. Cases were defined as women diagnosed with COVID-19 at any point during their pregnancy. Cases were matched with uninfected women who delivered in the same unit, within 30 d of the delivery of the index case. Outcomes of interest were frequencies of prematurity overall and subcategories of preterm birth (early, spontaneous/medically indicated, preterm labor, and premature preterm rupture of membranes) in cases compared to controls. The impact of modifiers of these outcomes was documented with extensive control for potential confounders. A p value \u3c.05 was used to infer significance.
RESULTS: The rate of prematurity was 8.9% in controls, 9.4% in asymptomatic cases, 26.5% in symptomatic COVID-19 cases, and 58.8% among cases admitted to the ICU. Gestational age at delivery was noted to decrease with disease severity. Cases were at an increased risk of prematurity overall [adjusted relative risk (aRR) = 1.62 (1.2-2.18)] and of early prematurity (\u3c34 weeks) [aRR = 1.8 (1.02-3.16)] when compared to controls. Medically indicated prematurity related to preeclampsia [aRR = 2.46 (1.47-4.12)] or other indications [aRR = 2.32 (1.12-4.79)], were the primary drivers of overall prematurity risk. Symptomatic cases were at an increased risk of preterm labor [aRR = 1.74 (1.04-2.8)] and spontaneous preterm birth due to premature preterm rupture of membranes [aRR = 2.2(1.05-4.55)] when compared to controls and asymptomatic cases combined. The gestational age at delivery followed a dose-response relation with disease severity, as more severe cases tended to deliver earlier (Wilcoxon p \u3c .05).
CONCLUSIONS: COVID-19 is an independent risk factor for preterm birth. The increased preterm birth rate in COVID-19 was primarily driven by medically indicated delivery, with preeclampsia as the principal risk factor. Symptomatic status and disease severity were significant drivers of preterm birth
